Spots Global Cancer Trial Database for cml
Every month we try and update this database with for cml cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study | NCT01657604 | Chronic Myeloid... | Peginterferon α... Nilotinib | 18 Years - | University of Jena | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01207440 | Chronic Myeloid... Ph+ Acute Lymph... | Ponatinib | 18 Years - | Takeda | |
| Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention | NCT02592447 | Chronic Myeloge... | Therapy for Tar... Wait-List Contr... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | NCT00488592 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1:126-134 PR1:169-177 Pep... GM-CSF (Sargram... Montanide adjuv... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) | NCT01751919 | Chronic Myeloid... Gastrointestina... | Imatinib mesyla... Glivec film-coa... | 20 Years - 50 Years | Dong-A ST Co., Ltd. | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia | NCT06163430 | Chronic Myeloid... Chronic Myeloid... | TERN-701 | 18 Years - | Terns, Inc. | |
| Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients | NCT01169753 | Chronic Myeloid... | Placebo Armodafinil | 18 Years - | M.D. Anderson Cancer Center | |
| CD34 Selection Using the Automated CliniMACS Prodigy | NCT06047886 | AML ALL Lymphoid Malign... Myelodysplastic... CML Primary Myelofi... | Infusion of CD3... | 4 Weeks - 75 Years | University of Alabama at Birmingham | |
| Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | NCT00038805 | Leukemia | Mylotarg | 55 Years - 75 Years | M.D. Anderson Cancer Center | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) | NCT00237120 | Chronic Myeloge... | Imatinib | 15 Years - 74 Years | Novartis | |
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | NCT00089596 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Non-Hodgkin Lym... Chronic Myeloge... | Expansion of um... | 12 Years - 60 Years | ViaCell | |
| Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients | NCT00386373 | Leukemia | Imatinib Mesyla... | 16 Years - | M.D. Anderson Cancer Center | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | NCT00405743 | Hematologic Mal... AML | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia | NCT05152537 | Folate CML Treatment-free ... | 18 Years - | Affiliated Hospital of Nantong University | ||
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | NCT00013533 | Hodgkin Lymphom... Lymphocytic Leu... Mixed Cell Leuk... Myelodysplastic... Non Hodgkin's L... CML ALL AML Lymphoma | Stem cell trans... | 4 Years - 20 Years | National Institutes of Health Clinical Center (CC) | |
| Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy | NCT00896129 | Chronic Myeloid... | HRQOL Survey Pa... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | NCT00375219 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| DC Vaccination in CML | NCT02543749 | Myeloid Leukemi... | DC vaccine | 18 Years - 80 Years | Charite University, Berlin, Germany | |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study | NCT01657604 | Chronic Myeloid... | Peginterferon α... Nilotinib | 18 Years - | University of Jena | |
| CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | NCT00710892 | Acute Lymphobla... Non-Hodgkin's L... Myelodysplastic... Chronic Myeloid... | Allodepleted T ... | - 65 Years | Baylor College of Medicine | |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | NCT02743351 | Hematologic Mal... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Acute Graft-ver... | ProTmune Control Arm | 18 Years - | Fate Therapeutics | |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | NCT00038818 | Chronic Myeloge... Multiple Myelom... Non Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | CD8 Depleted Do... | - | M.D. Anderson Cancer Center | |
| CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia | NCT06163430 | Chronic Myeloid... Chronic Myeloid... | TERN-701 | 18 Years - | Terns, Inc. | |
| Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | NCT01570868 | Leukemia | Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy | NCT03880617 | CML GIST | - | National Taiwan University Hospital | ||
| Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | NCT03678454 | Chronic Myeloid... CML Philadelphia Ch... Ph+ ALL | 18 Years - | Incyte Corporation | ||
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01019317 | Leukemia AML MDS CML | Cytarabine Fludarabine | 12 Years - | M.D. Anderson Cancer Center | |
| Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia | NCT00573378 | Chronic Myeloid... | PEG-IFN-a2b | 18 Years - | University of Michigan Rogel Cancer Center | |
| Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia | NCT01460693 | Myeloid Leukemi... | Imatinib Dasatinib | 18 Years - | Newcastle University | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | NCT00493181 | Leukemia Chronic Myeloge... Chronic Myeloid... | Interleukin-11 ... | - | M.D. Anderson Cancer Center | |
| Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses | NCT02467270 | Myeloid Leukemi... | Ponatinib | 18 Years - | Takeda | |
| A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) | NCT01751919 | Chronic Myeloid... Gastrointestina... | Imatinib mesyla... Glivec film-coa... | 20 Years - 50 Years | Dong-A ST Co., Ltd. | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | NCT00569179 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... | CliniMACS CD34 ... | 18 Years - 65 Years | Indiana University | |
| Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment | NCT03573596 | CML, Relapsed | Dasatinib | 18 Years - | Amsterdam UMC, location VUmc | |
| Stem Cell Transplantation for Patients With Cancers of the Blood | NCT00467961 | CML (Chronic My... CLL (Chronic Ly... AML (Acute Myel... Acute Lymphocyt... MDS (Myelodyspl... | Miltenyi system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) | NCT00050531 | Leukemia, Myelo... | Gleevec Peg-alpha inter... Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | NCT00109707 | Chronic Myeloge... Acute Lymphobla... Hypereosinophil... Systemic Mastoc... | Nilotinib | 18 Years - | Novartis | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT04126681 | Chronic Myeloid... | HQP1351 Hydroxyurea or ... Homoharringtoni... Imatinib, Dasat... | 18 Years - | Ascentage Pharma Group Inc. | |
| Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy | NCT01456676 | Philadelphia Ch... | Nilotinib + LDE... | 18 Years - | Novartis | |
| Special Drug Use-results Surveillance of Scemblix Tablets | NCT05421091 | Chronic Myeloid... | Asciminib | - 99 Years | Novartis | |
| Safety Assessment of a Multipeptide-gene Vaccine in CML | NCT00455221 | Leukemia, Myelo... | Bcr-abl multipe... Cytokine gene a... | 18 Years - 65 Years | Tehran University of Medical Sciences | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib | NCT01761890 | Chronic Myeloid... | Dasatinib disco... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Rasburicase in Patients at Risk for Tumor Lysis Syndrome | NCT00628628 | Tumor Lysis Syn... | As Needed Rasbu... Fixed Dose Rasb... | - | M.D. Anderson Cancer Center | |
| Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | NCT00038649 | Myelogenous Leu... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | NCT01606579 | Acute Myeloid L... Chronic Myeloid... | PRI-724 PRI-724 PRI-724 | 18 Years - | Prism Pharma Co., Ltd. | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | NCT00415909 | Chronic Myeloge... | Imatinib Mesyla... TALL-104 cells | 18 Years - | M.D. Anderson Cancer Center | |
| Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes | NCT00038870 | Acute Myelogeno... Chronic Myeloge... | Dendritic Cell ... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT04126681 | Chronic Myeloid... | HQP1351 Hydroxyurea or ... Homoharringtoni... Imatinib, Dasat... | 18 Years - | Ascentage Pharma Group Inc. | |
| Special Drug Use-results Surveillance of Scemblix Tablets | NCT05421091 | Chronic Myeloid... | Asciminib | - 99 Years | Novartis | |
| STI571 ProspectIve RandomIzed Trial: SPIRIT | NCT00219739 | Chronic Myeloid... | Imatinib mesyla... Imatinib mesyla... Imatinib 400 mg... Imatinib mesyla... | 18 Years - | Poitiers University Hospital | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) | NCT00760877 | CHRONIC MYELOGE... | Nilotinib Imatinib | 18 Years - | Novartis | |
| Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy | NCT03880617 | CML GIST | - | National Taiwan University Hospital | ||
| Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation | NCT01243489 | Chronic Myeloge... | compliance supp... | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
